Benitec Biopharma ROE 2014-2022 | BNTC
Current and historical return on equity (ROE) values for Benitec Biopharma (BNTC) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Benitec Biopharma ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2022-09-30 |
$-0.02B |
$0.02B |
-194.59% |
| 2022-06-30 |
$-0.02B |
$0.00B |
-194.59% |
| 2022-03-31 |
$-0.02B |
$0.01B |
-125.93% |
| 2021-12-31 |
$-0.02B |
$0.01B |
-126.32% |
| 2021-09-30 |
$-0.02B |
$0.02B |
-104.92% |
| 2021-06-30 |
$-0.01B |
$0.02B |
-103.70% |
| 2021-03-31 |
$-0.01B |
$0.01B |
-118.18% |
| 2020-12-31 |
$-0.01B |
$0.02B |
-133.33% |
| 2020-06-30 |
$-0.01B |
$0.01B |
-96.00% |
| 2020-03-31 |
$-0.01B |
|
-66.67% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.006B |
$0.000B |
|
Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.
|
